Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882527 | 0.89 | ALDH1A1 (0.55) | HPGDLMNASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL4883349 | 0.82 | CXCR2 (0.43) | HPGDLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8653894 | 0.79 | ALDH1A1 (0.52) | HPGDLMNASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL4888919 | 0.78 | HPGD (0.44) | HPGDLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4767657 | 0.77 | NLRP3 (0.69) | HPGDSMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL4883113 | 0.77 | HPGD (0.44) | HPGDSMN1; SMN2CYP1A2CYP2C19KMT2A | |
| SCHEMBL4883127 | 0.76 | TSHR (0.62) | MAPK1ALDH1A1 | |
| SCHEMBL4880034 | 0.76 | ALDH1A1 (0.47) | HPGDCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL6538988 | 0.75 | NLRP3 (0.62) | HPGDLMNASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL7250114 | 0.74 | ALDH1A1 (0.66) | HPGDLMNASMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | claimed |
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | GABRA5, GABRA1, GABRA4 | HPGD 2622/4885LMNA 3362/4885SMN1; SMN2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.